Pharmacodynamic Drug Interactions Mary Lynn McPherson, Pharm.D., BCPS Professor, University of Maryland School of Pharmacy mmcphers@rx.umaryland.edu Drug Interactions • Medications are used extensively to palliate symptoms – Patients with advanced illness take an average of 5 medications (range 0-13) – Increases risk for drug interactions – Risk increased due to patient fragility, comorbid conditions, increased age Defining a Drug Interaction • “A measurable modification (in magnitude or duration) of the action of one drug by prior or concomitant administration of another substance.” – Drug-drug (Rx, OTC, herbal) – Drug-food, drug-alcohol – Drug-lab, drug-disease, drug-chemical Wright 1992. Drug Interactions. In: Melmon and Morrelli’s Clinical Pharmacology 1992 Drug Interactions • Pharmacodynamics – The study of the action and effects of medications on physiologic function • Pharmacodynamic drug interactions can be: – Additive (two or more analgesics) – Synergistic – Antagonistic (dexamethasone and glyburide) Pharmacodynamic Drug Interactions in Palliative Care • • • • • • Anticholinergic effects Constipation Lowered seizure threshold Serotonin syndrome CNS depression QTc prolongation http://cwx.prenhall.com/bookbind/pubbooks/morris5/chapter2/custom1/deluxe-content.html Muscarinic Receptor Subtypes Receptor Subtype CNS Distribution Non-CNS Location M1 Cerebral cortex, hippocampus, neostriatum Salivary glands, sympathetic ganglia M2 Throughout the brain Smooth muscle, cardiac muscle M3 Low levels throughout brain Smooth muscle, salivary glands, eyes M4 Abundant in neostriatum, cortex and hippocampus Salivary glands M5 Projection neurons of substantia nigra Eyes (ciliary muscle) pars, compacta and ventral tegmental area and hippocampus Antimuscarinic Pharmacologic Effects: Peripheral • • • • Dry eyes Urinary retention Dry mouth Constipation • Heat intolerance • Tachycardia • Decreased sweating Carnahan et al. J Clin Pharmacol 2006;46:1481-1486 Antimuscarinic Pharmacologic Effects: Central • • • • Forgetfulness Agitation / confusion Delirium Paranoia • Dizziness • Drowsiness • Falls Carnahan et al. J Clin Pharmacol 2006;46:1481-1486 Evoking Antimuscarinic Effects Overactive bladder Anticholinergic / Antiparkinson’s Antivertigo / antiemetic • Oxybutynin (Ditropan) • Toleradine (Detrol) • Trospium (Sanctura) • Solifenacin (Vesicare) • Darifenacin (Enablex) • Trihexyphenidyl (Artane) • Benztropine (Cogentin) • Amantadine (Symmetrel) • Meclizine (Antivert) • Scopolamine (TransDerm Scop) Evoking Antimuscarinic Effects Gastrointestinal / Antispasmodics Antisecretory / Drying Agents Bronchospasm • Diphenoxylate (Lomotil) • Dicyclomine (Bentyl) • Hyoscyamine (Levsin) • Atropine (ophthalmic given PO) • Ipratroptium (Atrovent) • Tiotroptium (Spiriva) Antimuscarinic Adverse Effects Sedating Antihistamines • Diphenhydramine (Benadryl) • Hydroxyzine (Vistaril) Tricyclic Antidepressants • Amitriptyline (Elavil) • Nortriptyline (Pamelor) • Desipramine (Norpramin) • Doxepin (Sinequan) • Chlorpromazine (Thorazine) • Olanzapine (Zyprexa) • Clozapine (Clozaril) • Thioridazine (Mellaril) Antipsychotic Agents Antimuscarinic Adverse Effects Phenothiazines • Prochlorperazine (Compazine) • Promethazine (Phenergan) Antiarrhythmic Agents • Disopyramide (Norpace) Muscle relaxants • Cyclobenzaprine (Flexeril) • Orphenadrine (Norflex) Anticholinergic Activity of 107 Medications Commonly Used by Elders • Radioassay used to measure the anticholinergic activity of 107 medications • Categories included: 0 (non-detectable) 0/+ (no or minimal) + (0.5-5 pmol/ml) ++ (5-15 pmol/ml) +++ (> 15 pmol/ml) Chew et al. JAGS 2008;56:1333-1341. Anticholinergic Activity of 107 Medications Commonly Used by Elders • +++ (> 15 pmol/ml) – Amitriptyline, doxepin – Clozapine, thioridazine – Atropine, dicyclomine, hyoscyamine • ++ (5-15 pmol/ml) – – – – Nortriptyline, paroxetine Diphenhydramine Chlorpromazine, olanzapine Oxybutynin Chew et al. JAGS 2008;56:1333-1341. Anticholinergic Activity of 107 Medications Commonly Used by Elders • + (0.5-5 pmol/ml) – Citalopram, escitalopram, fluoxetine, mirtazpine – Quetiapine – Tempazepam – Ranitidine – Lithium Chew et al. JAGS 2008;56:1333-1341. Anticholinergic Activity of 107 Medications Commonly Used by Elders • 0/+ (no or minimal) – Celecoxib, fentanyl, hydrocodone, propoxyphene – Duloxetine, metformin – Amoxicillin, cephalexin, levofloxacin – Diazepam, donepezil – Digoxin, furosemide – Phenytoin, topiramate – Diphenoxylate, lansoprazole Chew et al. JAGS 2008;56:1333-1341. Anticholinergic Activity of 107 Medications Commonly Used by Elders • 0 (non-detectable) – Acetaminophen, aspirin, codeine, ibuprofen, morphine, tramadol – Bupropion, sertraline, trazodone, venlafaxine – Glipizide, pioglitazone, rosiglitazone – Cetirizine, fexofenadine, loratadine – Ciprofloxacin, sulfamethoxazole, trimethoprim – Aripiprazole, haloperidol, perphenazine, risperidonem ziprasidone Chew et al. JAGS 2008;56:1333-1341. Anticholinergic Activity of 107 Medications Commonly Used by Elders • 0 (non-detectable) – Alprazolam, buspirone, lorazepam, oxazepam, zaleplon, zolpidem – Beta-blockers, CCB, statins, ACE inhibitors, ARBs, nitroglycerin – Galantamine, memantine, rivastigmine – Bisacodyl, famotidine, loperamide, omeprazole, pantoprazole, rabeprazole Chew et al. JAGS 2008;56:1333-1341. Anticholinergic Activity of 107 Medications Commonly Used by Elders • 0 (non-detectable) – Baclofen, carbidopa, clopidogrel, darbepoetin, dipyridamole, epietin, levodopa, levothyroxine, megestrol, warfarin – Carbamazepine, gabapentin, lamotrigine, valproate Chew et al. JAGS 2008;56:1333-1341. Estimated Anticholinergic Activity (AA) for Therapeutic Doses of Nortriptyline at Estimated Mean Peak Concentrations (Cmax) in a Typical Geriatric Patient Total Daily Dose (mg) 10 25 50 100 150 Cmax (ng/ml) 12 29 59 117 175 In Vitro AA (pmol/ml) 0.8 3.5 8.2 18.0 29.0 Chew et al. JAGS 2008;56:1333-1341. Cognitive Impact of Anticholinergics • 27 studies reviewed • Consistent correlation seen between SAA and worsening performance on cognitive testing – Acute (delirium) – Chronic (mild cognitive impairment) • Deficits in processing, speed, psychomotor performance, concentration/attention, problem solving and language skills Campbell et al. Clinical Interventions in Aging 2009;4:225-233. Cognitive Impact of Anticholinergics • Delirium - identified by disorientation, altered consciousness, disorganized thinking, fluctuating alertness • Variable deficits in recalls identified • Minimal changes in global measures of cognitive functioning with exposure to anticholinergics Campbell et al. Clinical Interventions in Aging 2009;4:225-233. Anticholinergics Conclusion • Patients at risk – Older adults, advanced disease, fall risk – BPH, asthma – Taking other medications with similar adverse effects – Alzheimer’s disease and other dementias (anticholinergics antagonize cholinesterase inhibitors) • Consider non-drug interventions Constipation • 40% of all ADR affect the GI tract • Drug-induced constipation occurs at therapeutics doses of drugs and is dose-related • Medications most likely to cause constipation include: – – – – – – Antispasmodics (11.6%) Antihistamines (9.2%) Antidepressants (8.2%) Diuretics (5.6%) Aluminum antacids (3.0%) Opioids (2.6%) Talley NJ et al. Amer J Gastroenterology 2003;98:1107-1111. Drug-Induced Constipation Therapeutic Category Examples Analgesics Opioids (morphine), NSAIDs (ibuprofen) Anticholinergics TCA, antipsychotics (haloperidol), antiparkinsonian agents (benztropine), antihistamines (H1; diphenhydramine), antispasmodics (dicyclomine) Cation-containing agents Aluminum (antacids, sucralfate), calcium (antacids, supplements), bismuth, iron supplements, lithium Chemotherapy Vinca alkaloids (vincristine), alkylating agents (cyclophosphamide) Antihypertensives CCB (verapamil, nifedipine), diuretics (furosemide), centrally-acting (clonidine), antiarrhythmics (amiodarone), beta blockers (atenolol) Bile acid sequestrants Colestyramine, colestipol 5HT3-receptor antagonists Ondansetron Laxatives Chronic abuse Branch RL, Butt TF. Drug-induced constipation. Adverse Drug Reaction Bulletin 2009;257. Drug-Induced Constipation Therapeutic Category Examples Excess fiber Dietary or prescribed Other antidepressants Monoamine amine oxidase inhibitors Other antiparkinsonian agents Dopamine agonists Other antispasmodics Peppermint oil Anticonvulsants Carbamazepine Miscellaneous Barium sulphate, octreotide, polystyrene resins, oral contraceptives Vitamin C tablets, 131I thyroid ablation, erythropoietin, baclofen Pamidronate, alendronic acid, PPI and H2 antagonists Branch RL, Butt TF. Drug-induced constipation. Adverse Drug Reaction Bulletin 2009;257. Analgesics - Opioids • Mediated through either μ or δ-opioid receptors on enteric nerves, epithelial cells and muscle. – Reduces intestinal motility (via μ-receptors) – Reduces intestinal secretion (via δ-receptors) – And increases absorption of water (via μ and δreceptors) Analgesics - NSAIDs Inhibit cyclooxygenase, blocking production of PGE both centrally and peripherally. PGE Effects Inhibition of PGE Effects Decreases gastric acid secretion Increased gastric acid secretion Increases gastric mucus secretion Decreased mucus secretion Causes GI smooth muscle contraction GI smooth muscle relaxation NSAID discontinuation is more often due to constipation than dyspepsia. ↓ Constipation Other Drug-Induced Constipation • Anticholinergics – Inhibit PSNS, preventing Ach from binding to the M2 muscarinic receptor, resulting in decreased intestinal tone and motility. – Leads to a delay on colonic transfer time – Includes TCAs, MAOIs, antipsychotics, antiparkinsonian agents • Antispasmodics (peppermint oil) – Dose-related effect on smooth musculature caused by interference of menthol with the movement of calcium across the cell membrane. – Reduces influx of extracellular calcium ions through voltagedependent channels; reduces gastroduodenal motility by decreasing the number and amplitude of contractions. Other Drug-Induced Constipation • Cation-containing agents – Aluminum has an astringent effect and may cause intestinal obstruction in high doses. – 17-30% of aluminum chloride produced from aluminum hydroxide is absorbed; remainder unabsorbed from gut, producing constipating effect. – Calcium-containing antacids – 90% calcium carbonate is converted to insoluble calcium salts in small intestine, not absorbed, and cause constipation • Bismuth (bismuth subsalicylate; BSS) – BSS is an antidiarrheal agent; decreases flow of fluid and electrolytes into bowel, reducing inflammation in the intestine and killing organisms that cause diarrhea – Reduces number of formed stools by 50% • Iron, Lithium Other Drug-Induced Constipation • Chemotherapeutic agents – Vinca alkaloids – 50% of patients treated; due to neurologic changes in ANS or enteric NS – Alkylating agents (cyclophosphamide); denature proteins including in GIT. Changes in intestinal mucosa can cause constipation or diarrhea. • Antihypertensive agents – CCB (verapamil, nifedipine) – reduce intestinal motility – Diuretics (HCTZ) – decreased motility and excess fluid removal – Centrally-acting (clonidine) – stimulated absorption and inhibits secretion of fluids and electrolytes, prolongs intestinal transit time by interacting with receptors on enteric neurons • Amiodarone • Bile-acid sequestrants Drug-Induced Seizures • 6-9% of seizures are drug-induced • Drugs can cause seizures directly – At or above therapeutic concentrations • Drugs can cause seizures indirectly – Reducing the effectiveness of AED – Hypoglycemia, hyponatremia, hyperpyrexia – Due to adverse effects (hypoxia, arrhythmia or cerebral edema Thundiyil JG et al. J Medical Tech 2007;3:15-19. Thundiyil JG et al. J Medical Tech 2007;3:15-19. Drug-Induced Seizures • Cases involving TCAs, cocaine and theophylline have shown a marked decrease • Newer causes of drug-induced causes have emerged including: bupropion, tramadol, and venlafaxine Drug Withdrawal-Induced Seizures • • • • • Anticonvulsant agents Benzodiazepines Barbiturates Opioids Baclofen Serotonin Syndrome • A potentially life-threatening condition caused by excess serotonergic stimulation of the central nervous system. • Caused by: – Drug interactions – Intentional overdose • Symptoms occur within minutes to hours after starting a second drug Serotonin Syndrome • Classic triad of symptoms – Altered mental status – Neuromuscular hyperactivity – Autonomic hyperactivity • All three features are not always present together Clinical Features of Serotonin Syndrome • Neuromuscular hyperactivity – – – – – – Akathisia Tremor Clonus Myoclonus Rigidity Nystagmus • Autonomic hyperactivity – – – – Diaphoresis Fever Tachycardia Tachypnea • Altered mental status – Agitation – Excitement – Confusion Sun-Edelstein. Expert Opin Drug Safe 2008;7:587-596 Boyer EW et al. NEJM 352;1112-1130. Drug-Induced Serotonin Syndrome TheraCategory Examples SSRIs Paroxetine, sertraline, fluoxetine, fluvoxamine, citalopram SNRIs Venlafaxine, milnacipran, duloxetine, sibutramine TCAs Clomipramine, imipramine Misc Antidepress Mirtazapine, trazodone, St. John’s Wort Maoist Trancylcpromine, phenelzine, isocarboxazid Antiparkinsons Selegilene Anti-infectives Linezolid, furazolidone Opioids Meperidine, fentanyl, methadone, tramadol, pentazocine, dextromethorphan Antihistamines Chlorpheniramine, brompheniramine CNS stimulants / Psychedelics Amphetamine, sibutramine, methylphenidate, cocaine, MDMA (ectasy), LSD Triptans (+/-) Sumatriptan, zolmitriptan, rizatriptan, almotriptan, frovatriptan Sun-Edelstein. Expert Opin Drug Safe 2008;7:587-596 Suspecting Serotonin Syndrome • Was a serotonergic agent administered in the past five weeks? – No – stop; Yes –continue • Experienced one of the following: – Tremor and hyperreflexia – Spontaneous clonus – Muscle ridigity, temperature > 38°C and either ocular clonus or inducible clonus – Ocular clonus, and either agitation or diaphoresis – Inducible clonus and either agitation or diaphoresis • No – stop; Yes – possibly serotonin syndrome Boyer EW et al. NEJM 352;1112-1130. Drug-induced CNS depression • • • • • • • Sedation, agitation, confusion May progress to respiratory depression Opioids, benzodiazepines Non-benzodiazepine sedative-hypnotics Barbiturates, alcohol, antipsychotics Antidepressants, antihistamines (H1) Antiemetics, anticonvulsants, illicit drugs Drug-induced CNS depression • Less obvious causes: – Cimetidine – Anticholinergic agents – Drugs that reduce GFR • NSAIDs • ACE inhibitors • Fall risk increased with: – Sedatives, hypnotics, antidepressants, benzodiazepines Opioid-Induced Sedation • Occurs in 20-60% patients taking opioids • Sedation is defined as “depression of brain functioning by a medication, mainfested by sleepiness, drowsiness, fatigue, slowed brain activity, reduced wakefulness, and impaired performance.” • Dose-dependent effect • Tolerance within a few days • Don’t confuse with “catch-up” sleep Opioid-Induced Respiratory Depression • Quantified by – Observed changes in breathing frequency • Severe respiratory depression considered to be breathing rate of less than 8-10 breaths/minute – And/or oxygen saturation • Slowed and irregular respiration leads to hypercapnia and hypoxia Factors that modulate opioidinduced respiratory depression • Drug interactions – Propofol, midiazolam • Sleep – obstructive sleep apnea – Opioids increase stage 2 sleep (light sleep) and decrease stage 4 (deep sleep) and REM sleep – Methadone and benzodiazepines • Pain – stimulated respiration Pattinson KTS. Br J Anaesth 2008;100:747-758. Factors that modulate opioidinduced respiratory depression • Genetics • Polymorphisms affecting MOP receptor activity and opioid bioavailability • Polymorphisms affecting opioid metabolism Pattinson KTS. Br J Anaesth 2008;100:747-758. Atypical Opioids and Respiratory Depression • Tramadol – Causes less respiratory depression than meperidine or oxycodone at equivalent doses – Reported in patients with renal failure • Buprenorphine – Partial agonist; may cause less respiratory depression than conventional opioids at equivalent doses Pattinson KTS. Br J Anaesth 2008;100:747-758. Drug-Induced QTc Prolongation • QT interval prolongation is an abnormality of the electrical activity of the heart that places individuals at risk for ventricular arrhythmias. – > 450 msec in men; > 470 msec in women • Increase in QTc > 60 msec from baseline after medication administration, or • QTc values > 500 msec after medication adminstration – Potential risk for arrhythmia, including Torsades de Pointes (TdP) Risk Factors for Drug-Induced QTc Prolongation • Female sex • Hypokalemia • Severe hypomagnesemia • Bradycardia • Recent conversion from atrial fibrillation • Congestive heart failure Wood AJJ. NEJM 2004;350:1013-1022. • Subclinical long QT syndrome (LQTS) • Baseline QT interval prolongation • Ion-channel polymorphisms • Medications / high serum concentrations / rapid infusion Drugs that may cause TdP • Drugs commonly involved – Disopyramide, dofetilide, ibutilide – Procainamide, quinidine, sotalol, bepridil • Other drugs – Amiodarone, arsenic trioxide, cisapride – Erythromycin, clarithyromycin, halofantrine, pentamidine, sparfloxacin, chloroquine – Domperidone, droperidol – Chlorpromazine, haloperidol, thioridazine – Methadone Gupta A et all Am Heart J 2007;153:891-899. Methadone and LQTS and TdP • Increasingly prescribed for chronic pain • Associated mortality rising disproportionately relative to other opioids • Potent blocker of delayed rectifier potassium ion channel • Results in QT-prolongation and TdP in susceptible individuals Risk Factors for Methadone and Prolonged QTc • Dose-related • Inappropriate initial dosing (including drug diversion) or conversion calculation • Sleep apnea, heart/lung/liver disease • Use of other drugs that increase risk www.torsades.org • Arizona CERT – Center for Education and Research on Therapeutics – – – – Drugs with known risk of TdP Drugs with possible risks of TdP Drugs for LQTS patients to avoid Drugs unlikely to cause TdP Pharmacodynamic Drug Interactions in Palliative Care • • • • • • Anticholinergic effects Constipation Lowered seizure threshold Serotonin syndrome CNS depression QTc prolongation Questions